buprenorphine/naloxone vs glecaprevir/pibrentasvir
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of buprenorphine/naloxone and glecaprevir/pibrentasvir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
↑= increase; ↓= decrease; ↔ = no effect 7.4 Medication-Assisted Treatment (MAT) for Opioid Use Disorder No buprenorphine/naloxone or methadone dosage adjustment is required when used concomitantly with MAVYRET.
Suboxone
Mavyret
Suboxone film contains buprenorphine and naloxone. It is used to treat opioid dependence as part of a complete treatment plan.
Mavyret is a medicine used to treat hepatitis C (HCV) in adults and children 3 years and older. It contains two drugs, glecaprevir and pibrentasvir, that work together to stop the virus from multiplying.
Suboxone film is used to treat opioid dependence. Opioid dependence means you are addicted to opioid drugs. This medicine should be used with counseling and support.
Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6. It can be used in people without cirrhosis or with compensated cirrhosis. Mavyret can also treat genotype 1 in people who have already been treated with certain other HCV medicines.
Buprenorphine is a partial opioid agonist, meaning it has some opioid effects. Naloxone is an opioid antagonist, which blocks the effects of opioids. Together, they help reduce cravings and withdrawal symptoms without causing a strong "high."
Mavyret contains glecaprevir and pibrentasvir. Glecaprevir blocks a protein called NS3/4A protease that the virus needs to multiply. Pibrentasvir blocks a protein called NS5A, also needed for the virus to multiply. By blocking these proteins, Mavyret stops the hepatitis C virus from spreading in your body.
- • Mouth numbness
- • Tongue pain
- • Mouth redness
- • Headache
- • Feeling sick to your stomach
- • Headache
- • Feeling tired
- • Nausea
- Feeling sick to your stomach 138
- Throwing up 92
- Reaction at the injection site 90
- Headache 79
- Problem with the medicine being substituted 73
- Feeling tired 2,561
- Headache 2,203
- Nausea 1,125
- Itching 653
- Diarrhea 477
Buprenorphine can be abused, like other opioids. Taking Suboxone with other depressants like alcohol or benzodiazepines can cause serious breathing problems, coma, or death. Keep Suboxone out of the reach of children, as it can cause severe breathing problems and death if they take it. Using opioids for a long time during pregnancy can cause withdrawal symptoms in the newborn.
Mavyret can cause hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Your doctor will test you for hepatitis B before you start Mavyret. They will also monitor you during and after treatment.
If you are pregnant or plan to become pregnant, talk to your doctor. Using Suboxone during pregnancy can cause withdrawal symptoms in the baby after birth. Buprenorphine passes into breast milk, so talk to your doctor before breastfeeding.
It is not known if Mavyret will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Mavyret passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking Mavyret.
How to Read This buprenorphine/naloxone vs glecaprevir/pibrentasvir Comparison
buprenorphine/naloxone is classified in the Partial Opioid Agonist / Antagonist drug class, while glecaprevir/pibrentasvir sits within the NS3/4A/NS5A Inhibitor (HCV) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, buprenorphine/naloxone has 472 submissions while glecaprevir/pibrentasvir has 7,019. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to these medications do not interfere with each other's levels in the blood or how they work in the body.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for buprenorphine/naloxone or glecaprevir/pibrentasvir.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.